Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, Blomquist P, Zaidi A, Volz E, Aziz NA, Harman K, Funk S, Abbott S; COVID-19 Genomics UK (COG-UK) consortium; Hope R, Charlett A, Chand M, Ghani AC, Seaman SR, Dabrera G, De Angelis D, Presanis AM, Thelwall S. Nyberg T, et al. Among authors: harman k. Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16. Lancet. 2022. PMID: 35305296 Free PMC article.
Interpretation of COVID-19 case fatality risk measures in England.
Harman K, Allen H, Kall M, Dabrera G. Harman K, et al. J Epidemiol Community Health. 2021 Jan 29:jech-2020-216140. doi: 10.1136/jech-2020-216140. Online ahead of print. J Epidemiol Community Health. 2021. PMID: 33514625 No abstract available.
Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages.
Nyberg T, Harman K, Zaidi A, Seaman SR, Andrews N, Nash SG, Charlett A, Lopez Bernal J, Myers R, Groves N, Gallagher E, Gharbia S, Chand M, Thelwall S, De Angelis D, Dabrera G, Presanis AM. Nyberg T, et al. Among authors: harman k. J Infect Dis. 2022 Sep 13;226(5):808-811. doi: 10.1093/infdis/jiac063. J Infect Dis. 2022. PMID: 35184201 Free PMC article.
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.
Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J, Blomquist PB, Hope R, Ashano E, Myers R, Rokadiya S, Hopkins S, Brown CS, Chand M, Dabrera G, Thelwall S. Harman K, et al. Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150. Influenza Other Respir Viruses. 2023. PMID: 37246147 Free PMC article.
Representativeness of whole-genome sequencing approaches in England: the importance for understanding inequalities associated with SARS-CoV-2 infection.
Twohig KA, Harman K, Zaidi A, Aliabadi S, Nash SG, Sinnathamby M, Harrison I, Gallagher E, Groves N, Schwach F, Pearson C, Thornton A, Myers R, Chand M, Thelwall S, Dabrera G. Twohig KA, et al. Among authors: harman k. Epidemiol Infect. 2023 Sep 20;151:e169. doi: 10.1017/S0950268823001541. Epidemiol Infect. 2023. PMID: 37726109 Free PMC article.
COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Bou-Antoun S, Rokadiya S, Ashiru-Oredope D, Demirjian A, Sherwood E, Ellaby N, Gerver S, Grossi C, Harman K, Hartman H, Lochen A, Ragonnet-Cronin M, Squire H, Sutton JM, Thelwall S, Tree J, Bahar MW, Stuart DI, Brown CS, Chand M, Hopkins S. Bou-Antoun S, et al. Among authors: harman k. J Antimicrob Chemother. 2023 Nov 23;78(Suppl 2):ii37-ii42. doi: 10.1093/jac/dkad314. J Antimicrob Chemother. 2023. PMID: 37995354 Free PMC article.
221 results